UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

The New England journal of medicine, 2014-05, Vol.370 (21), p.1973-1982

2014

Volltextzugriff (PDF)

Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy

Hepatology (Baltimore, Md.), 2020-07, Vol.72 (1), p.42-57

2020

Volltextzugriff (PDF)

Treatment of Genotype 3 Chronic Hepatitis C Virus Infection

Clinical Medicine Insights: Therapeutics, 2017-03, Vol.2017 (9), p.1

2017

Volltextzugriff (PDF)

Review article: novel biomarkers in hepatitis B infection

Alimentary pharmacology & therapeutics, 2022-09, Vol.56 (5), p.760-776

2022

Volltextzugriff (PDF)

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Journal of hepatology, 2019-12, Vol.71 (6), p.1099-1105

2019

Volltextzugriff (PDF)

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Journal of hepatology, 2016-10, Vol.65 (4), p.741-747

2016

Volltextzugriff (PDF)

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Journal of hepatology, 2016-07, Vol.65 (1), p.33-39

2016

Volltextzugriff (PDF)

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Journal of hepatology, 2017-08, Vol.67 (2), p.224-236

2017

Volltextzugriff (PDF)

Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study

Clinical therapeutics, 2024-02, Vol.46 (2), p.159-163

2024

Volltextzugriff (PDF)

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

The New England journal of medicine, 2014-05, Vol.370 (21), p.1993-2001

2014

Volltextzugriff (PDF)

Recurrent HCV after liver transplantation-mechanisms, assessment and therapy

Nature reviews. Gastroenterology & hepatology, 2014-12, Vol.11 (12), p.710

2014

Volltextzugriff (PDF)

Reply to: “Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action”

Journal of hepatology, 2020-03, Vol.72 (3), p.585-586

2020

Volltextzugriff (PDF)

The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C

Antiviral therapy, 2018, Vol.23 (6), p.539-542

2018

Volltextzugriff (PDF)

Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything

Journal of hepatology, 2018-01, Vol.68 (1), p.217-218

2018

Volltextzugriff (PDF)

Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation

Liver transplantation, 2020-06, Vol.26 (6), p.811-822

2020

Volltextzugriff (PDF)

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa

The Journal of infectious diseases, 2022-09, Vol.226 (6), p.995-1004

2022

Volltextzugriff (PDF)

Efficacy and Tolerability of Direct‐Acting Antivirals for Hepatitis C in Older Adults

Journal of the American Geriatrics Society (JAGS), 2018-07, Vol.66 (7), p.1339-1345

2018

Volltextzugriff (PDF)

Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries

Journal of hepatology, 2017-12, Vol.67 (6), p.1348-1350

2017

Volltextzugriff (PDF)

Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia

AIDS (London), 2013-06, Vol.27 (9), p.1443-1448

2013

Volltextzugriff (PDF)

Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”

Journal of hepatology, 2018-04, Vol.68 (4), p.864-866

2018

Volltextzugriff (PDF)

The Protease Inhibitor, GS-9256, and Non-Nucleoside Polymerase Inhibitor Tegobuvir Alone, With Ribavirin, or Pegyrlated Interferon Plus Ribavirin in Hepatitis C

Hepatology (Baltimore, Md.), 2012, Vol.55 (3), p.749-758

2012

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Viral Hepatitis

ThemaAntiviral Agents

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy

Treatment of Genotype 3 Chronic Hepatitis C Virus Infection

Review article: novel biomarkers in hepatitis B infection

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Recurrent HCV after liver transplantation-mechanisms, assessment and therapy

Reply to: “Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action”

The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C

Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything

Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study

Efficacy and Tolerability of Direct‐Acting Antivirals for Hepatitis C in Older Adults

Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries

Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia

Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”

The Protease Inhibitor, GS-9256, and Non-Nucleoside Polymerase Inhibitor Tegobuvir Alone, With Ribavirin, or Pegyrlated Interferon Plus Ribavirin in Hepatitis C

Aktive Filter

Suchergebnisse filtern